Dalbavancin Hydrochloride Patent Expiration

Dalbavancin Hydrochloride is Used for treating acute bacterial skin and skin structure infections (ABSSSI) in both adults and pediatric patients. It was first introduced by Abbvie Inc in its drug Dalvance on May 23, 2014.


Dalbavancin Hydrochloride Patents

Given below is the list of patents protecting Dalbavancin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Dalvance US6900175 Methods of administering dalbavancin for treatment of bacterial infections May 23, 2028 Abbvie
Dalvance US7115564 Stable pharmaceutical compositions of dalbavancin and methods of administration Nov 14, 2023

(Expired)

Abbvie
Dalvance US7119061 Dalbavancin compositions for treatment of bacterial infections Nov 14, 2023

(Expired)

Abbvie
Dalvance US8143212 Dalbavancin compositions for treatment of bacterial infections Nov 14, 2023

(Expired)

Abbvie


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳